S-1: Lifeward Ltd. Files S-1 for Public Offering Amidst Going Concern Doubts, Seeks $3.6 Million to Fund Operations

Lifeward Ltd., a medical device company, has filed an S-1 registration statement to offer up to 4,000,000 ordinary shares and warrants, aiming to raise approximately $3.6 million in net proceeds, while acknowledging substantial doubt about its ability to continue as a going concern.

Summary

• Lifeward Ltd. is offering up to 4,000,000 ordinary shares and accompanying warrants, or pre-funded warrants and accompanying warrants, with an assumed combined public offering price of $1.07 per ordinary share and warrant.
• The offering also includes up to 240,000 Placement Agent Warrants, with a total of up to 8,240,000 ordinary shares issuable upon exercise of all warrants.
• The estimated net proceeds from this offering are approximately $3.6 million, assuming the maximum sale of securities and no exercise of warrants, which will be used for continuing commercial efforts, working capital, and general corporate purposes.
• As of March 31, 2025, the company reported an accumulated deficit of approximately $269.7 million, raising substantial doubt about its ability to continue as a going concern.
• New investors in this offering will experience an immediate dilution of $0.08 per share in the as-adjusted net tangible book value.
• The exercisability of the main warrants is contingent upon obtaining shareholder approval, which may not be secured.
• Lifeward's product portfolio includes ReWalk Personal and Rehabilitation Exoskeleton devices for spinal cord injury, ReStore Exo-Suit for stroke rehabilitation, and AlterG Anti-Gravity systems (acquired August 2023).
• The company recently announced an exclusive distribution agreement with CorLife, LLC for the ReWalk Personal Exoskeleton in the workers' compensation market.
• Development of the ReBoot personal soft exo-suit for post-stroke use, which received FDA Breakthrough Device Designation in November 2021, was paused in 2023 pending further evaluation.

Sentiment

Score: 3

Explanation: The company is undertaking a capital raise, which is positive for liquidity, but the significant accumulated deficit and explicit 'going concern' warning indicate severe financial distress. While product diversification and strategic partnerships are positive, the underlying financial health is a major concern, leading to a low sentiment score.

Positives

• FDA clearance for ReWalk Personal Exoskeleton with stair and curb functionality in March 2023 expands device utility.
• Acquisition of AlterG in August 2023 for approximately $19 million cash broadens product offerings in physical and neurological rehabilitation.
• Strategic partnership with CorLife, LLC (a division of Numotion) in March 2025 is expected to increase penetration of SCI Products into the workers' compensation market and facilitate claims processing.
• The company continues to evaluate other products for distribution or acquisition to further expand its offerings for individuals with neurological injury and disability.

Negatives

• The company has an accumulated deficit of approximately $269.7 million as of March 31, 2025.
• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern.
• The offering is on a 'reasonable best efforts' basis with no minimum amount, meaning the actual proceeds may be substantially less than the maximum target.
• New investors will experience immediate dilution of $0.08 per share in net tangible book value.
• The exercisability of the Warrants is contingent upon shareholder approval, and if not obtained, the Warrants may never become exercisable and will have no value.
• There is no established public trading market for the Warrants or Pre-Funded Warrants, limiting their liquidity.
• The company has no current plans to pay cash dividends in the foreseeable future.
• Development of the ReBoot personal soft exo-suit was paused in 2023 and remains on hold.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern, potentially leading to insolvency and loss of investment.
• The company will require additional capital funding, which may result in substantial dilution to existing shareholders and new equity securities potentially having greater rights.
• The 'reasonable best efforts' nature of the offering means the company may sell fewer than all securities, reducing proceeds and potentially hindering business objectives.
• Management has broad discretion over the use of offering proceeds, which may not be used effectively to improve operating results or enhance share value.
• The exercisability of the Warrants is contingent upon shareholder approval, and failure to obtain it could render the Warrants valueless.
• Future equity offerings or other equity issuances could cause further dilution to ownership interests.
• Future sales of ordinary shares, or the perception of such sales, could cause the share price to decline.
• Purchasers entering into a securities purchase agreement may have rights not available to other purchasers, including specific covenants and indemnification.
• There is no public market for the Warrants and Pre-Funded Warrants, limiting their liquidity.
• Holders of Warrants and Pre-Funded Warrants have no shareholder rights until exercise, except as explicitly set forth in the warrant terms.
• The Warrants and Pre-Funded Warrants are speculative in nature, and there is no assurance the ordinary share market price will exceed their exercise price.
• The market price and trading volume of the company's ordinary shares may be volatile due to various factors, including company performance, industry trends, and market conditions.
• The company may be classified as a Passive Foreign Investment Company (PFIC), subjecting U.S. Holders to adverse tax rules.
• Compliance with Israel Innovation Authority (IIA) grant terms restricts transfer of know-how or manufacturing outside Israel without prior approval, potentially increasing royalty rates.
• Risk of cybersecurity attacks or incidents relating to IT Systems and Data.
• Potential impact of global instability, including the Russia-Ukraine conflict, Middle East conflict, and China-Taiwan tensions, on business operations or financial condition.

Future Outlook

The company intends to use the net proceeds from this offering for continuing commercial efforts, working capital, and general corporate purposes. It will continue to evaluate other products for distribution or acquisition to broaden its offerings. The company acknowledges that its ability to continue as a going concern depends on obtaining necessary financing and that future capital requirements are dependent on research, development, sales, and marketing activities. The company aims to maintain its Nasdaq listing and will seek shareholder approval for warrant exercisability.

Management Comments

• Management concluded that substantial doubt about the company's ability to continue as a going concern exists as of the date of the issuance of these financial statements.
• The company believes the agreement with CorLife will build awareness of the benefits of the ReWalk Personal Exoskeleton and facilitate efficient processing of claims.
• The company intends to use the net proceeds from this offering for continuing commercial efforts, working capital, and general corporate purposes.

Industry Context

Lifeward operates in the medical device industry, specifically focusing on physical rehabilitation and recovery. The company's strategy involves both internal development and strategic acquisitions/distribution agreements to expand its product offerings beyond spinal cord injury (SCI) exoskeletons to include solutions for stroke rehabilitation and anti-gravity systems. This diversification aligns with broader trends in the healthcare sector seeking comprehensive rehabilitation solutions and leveraging technology for improved patient outcomes. The focus on workers' compensation market penetration indicates an effort to tap into specific reimbursement channels within the U.S. healthcare system.

Management Changes

Corporate Governance

Legal Proceedings

• A past securities class action against Lifeward was dismissed in full in November 2020.
• There are no pending or, to the company's knowledge, threatened actions, suits, inquiries, or investigations against the company or its subsidiaries that would have a Material Adverse Effect.

Related Party Transactions

• Except as disclosed on Schedule 3.1(r), none of the officers or directors of the Company or any Subsidiary, nor any employees, are party to any transaction with the Company or any Subsidiary in excess of $120,000, other than for salary, consulting fees, expense reimbursements, and other employee benefits including equity-based compensation.

Stakeholder Impact

• **Shareholders**: Will experience immediate and potential future dilution due to the offering and future equity issuances. Face significant risk due to the company's 'going concern' warning and lack of dividends. Existing shareholders may see their equity interests' value reduced by hedging activities of purchasers.
• **Employees**: Employment terms and equity incentive plans are in place, but the company's financial challenges could impact job security or future compensation.
• **Customers**: Continued commercial efforts and product development (funded by the offering) aim to ensure product availability and support for users of rehabilitation devices.
• **Creditors**: The capital raise is intended to provide working capital, which could help the company meet its existing and expected obligations, but the 'going concern' warning indicates ongoing financial risk.

Next Steps

• The company will seek shareholder approval for the issuance of ordinary shares upon exercise of the Warrants at a meeting on or prior to 90 days following the Closing Date.
• If shareholder approval is not obtained at the first meeting, the company will call a meeting every 90 days thereafter until approval is received or the Warrants are no longer outstanding.
• The company intends to use the net proceeds for continuing commercial efforts, working capital, and general corporate purposes.
• The company will continue to evaluate other products for distribution or acquisition to broaden its product offerings.

Key Dates

Recommendation

Keywords

Medical Device, Rehabilitation, Exoskeleton, SEC Filing, S-1, Public Offering, Warrants, Pre-Funded Warrants, Capital Raise, Going Concern, Nasdaq, Spinal Cord Injury, Stroke Rehabilitation, AlterG, CorLife